[Effect of pamidronate infusion time on renal function in patients with multiple myeloma].
BACKGROUND
Administration of biphosphonates in patients with renal failure requires a dosage adjustment.


OBJECTIVE
Analyse renal function evolution in multiple myeloma patients after reducing infusion time for 90 mg pamidronate by 2 h.


METHODS
In 2007, a retrospective study was carried out on all patients who presented multiple myeloma and bone metastasis treated with pamidronate administered every 4 h. Following a review of the literature, a protocol for administering pamidronate every 2 h was created in partnership with Haematology, and a specific dose reduction framework was established for patients with baseline renal failure. Additionally, a prospective follow-up study of those patients' renal function was completed to analyse its evolution after the change in infusion time.


RESULTS
A total of six patients received 90 mg pamidronate every 4 h. 33.32% of the patients (2/6) presented baseline renal insufficiency, and therefore needed to have the pamidronate dose adjusted according to the new protocol. Subsequently, all of them received the treatment every 2 h, and one patient (16.6%) experienced altered renal function after two treatment cycles.


CONCLUSIONS
Reducing administration time for pamidronate from four to 2 h did not lead to significant variations in patients' renal function. This therapeutic practice can improve patients' quality of life by shortening their hospital stay without aggravating their renal function.
Servicio de Farmacia, Area de Gestión Sanitaria Norte de Almería, Huércal-Overa, Almería, Spain. currosg@hotmail.com
F
F
Sierra
E
E
Román
C
C
Barreda
M
M
Moleón
J
J
Pastor
A
A
Navarro
D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D009101:Multiple Myeloma / Q000503:physiopathology; D000077268:Pamidronate; D012189:Retrospective Studies; D013997:Time Factors
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000077268:Pamidronate